<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687384</url>
  </required_header>
  <id_info>
    <org_study_id>75709</org_study_id>
    <nct_id>NCT04687384</nct_id>
  </id_info>
  <brief_title>Systemic and Peritoneal Inflammatory Response In Robotic-assisted And Laparoscopic Surgery for Colon Cancer</brief_title>
  <official_title>Systemic and Peritoneal Inflammatory Response In Robotic-assisted And Laparoscopic Surgery for Colon Cancer (SIRIRALS-trial): a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current hypothesis is that robotic-assisted surgery results in a reduced systemic and&#xD;
      peritoneal inflammatory response (SIRS) compared to laparoscopic surgery in the treatment of&#xD;
      colon cancer. The purpose is to evaluate differences in the peritoneal and systemic&#xD;
      inflammatory response in robot-assisted and laparoscopic surgery of patients undergoing&#xD;
      resection for colon cancer in a randomized, blinded controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in levels of systemic inflammatory response expressed by CRP and IL-6 in serum between the two groups</measure>
    <time_frame>Baseline and postoperative (day 1-3)</time_frame>
    <description>CRP (mg/L), IL-6 (pg/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of systemic inflammation in serum between the two groups</measure>
    <time_frame>Baseline and postoperative (day 1-3)</time_frame>
    <description>The cytokine levels are expressed by: Eotaxin, Eotaxin-3, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-7, IL-8, IL-8 (HA), IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC, TNF-α, TNF-β, VEGF-A and IL-1RA. All cytokines are measured in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in number of patients with postoperative surgical and medical complications (30 days) according to Clavien-Dindo classification and Comprehensive Complication Index (CCI)</measure>
    <time_frame>30 days</time_frame>
    <description>Number of complications obtained from medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in intraoperative blood loss</measure>
    <time_frame>1 day</time_frame>
    <description>Measured in mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate to open surgery</measure>
    <time_frame>1 day</time_frame>
    <description>Number of conversions to open surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of surgery (total anesthesia time)</measure>
    <time_frame>1 day</time_frame>
    <description>Measured in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of surgery (total surgical time)</measure>
    <time_frame>1 day</time_frame>
    <description>Measured in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node yield</measure>
    <time_frame>14 days</time_frame>
    <description>Pathological examination of lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>14 days</time_frame>
    <description>Measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Baseline and postoperative (day 1-3 and 14)</time_frame>
    <description>Measured by VAS-scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>Postoperative (day 1-3)</time_frame>
    <description>Measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first bowel movement</measure>
    <time_frame>Postoperative (day 1-3)</time_frame>
    <description>Measured in hours</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Levels of peritoneal inflammatory response in peritoneal fluid</measure>
    <time_frame>Postoperative (day 1-3)</time_frame>
    <description>Levels of cytokines are expressed by: Eotaxin, Eotaxin-3, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-8 (HA), IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC, TNF-α, TNF-β, VEGF-A as well as IL-1RA and CRP. All cytokines are measured in pg/mL, CRP measured in mg/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported health related quality of recovery (QoR-15)</measure>
    <time_frame>Baseline and postoperative (day 1-3 and 14)</time_frame>
    <description>Recovery is measured according to quality of recovery 15 score (QoR-15). The score ranges from 0-150. A high score indicates a good recovery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of mortality obtained from medical charts</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>Postoperative (day 1-3)</time_frame>
    <description>The heart rate will continuously recorded by ECG intra- and postoperatively</description>
  </other_outcome>
  <other_outcome>
    <measure>Whole blood gene expression profiling</measure>
    <time_frame>Baseline and postoperative (day 1-3)</time_frame>
    <description>Gene mRNA transcript analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to local cancer recurrence or metastatic spread</measure>
    <time_frame>3 years postoperatively</time_frame>
    <description>The two surgical methods will be compared in order to obtain any differences in the local or metastatic cancer recurrence</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colonic Neoplasms</condition>
  <condition>Colon Cancer</condition>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Inflammation</condition>
  <condition>Robotic Surgical Procedures</condition>
  <condition>Laparoscopy</condition>
  <condition>Peritoneal Inflammation</condition>
  <arm_group>
    <arm_group_label>Robotic-assisted surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing robotic-assisted colectomy for colonic neoplasm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing conventional laparoscopic colectomy for colonic neoplasm</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic-assisted colectomy</intervention_name>
    <description>Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology</description>
    <arm_group_label>Robotic-assisted surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional laparoscopic colectomy</intervention_name>
    <description>Conventional laparoscopic colectomy</description>
    <arm_group_label>Laparoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Elective robotic-assisted or laparoscopic surgery for right-sided, left-sided and&#xD;
             sigmoid colon cancer&#xD;
&#xD;
          -  Aged ≥ 18&#xD;
&#xD;
          -  ASA-score ≤ 3&#xD;
&#xD;
          -  Tumor-stage (Tx-T4a)&#xD;
&#xD;
          -  Endoscopic suspected colon cancer&#xD;
&#xD;
          -  Histological verified adenocarcinoma, signet ring cell carcinoma, undifferentiated&#xD;
             cancer, medullary carcinoma, or another malignant tumor type originating from colon&#xD;
&#xD;
          -  Patients must give informed written consent&#xD;
&#xD;
          -  Patients must be able to understand Danish language&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Carcinoma of the transverse colon or synchronous colorectal cancer&#xD;
&#xD;
          -  Previous history of colon cancer&#xD;
&#xD;
          -  Previous open major abdominal surgery with exception of open appendectomy and&#xD;
             cholecystectomy.&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of psychiatric or addictive disorder that would prevent the patient from&#xD;
             participating in the trial&#xD;
&#xD;
          -  Emergency colon surgery&#xD;
&#xD;
          -  Co-existing inflammatory bowel disease&#xD;
&#xD;
          -  Co-existing immunological disease that requiring ingestion of systemic&#xD;
             immunomodulatory drugs (DMARD - disease modifying anti-rheumatic drugs),&#xD;
             corticosteroids and biologic disease-modifying anti-rheumatic drugs.&#xD;
&#xD;
          -  Daily consumption of NSAID drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedja Cuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surgical Department, Hospital of Southern Jutland, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedja Cuk, MD</last_name>
    <phone>+4579970000</phone>
    <email>pedja.cuk@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Southern Denmark</name>
      <address>
        <city>Aabenraa</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedja Cuk, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pedja Cuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic inflammatory response</keyword>
  <keyword>Colonic neoplasm</keyword>
  <keyword>Robotic assisted surgery</keyword>
  <keyword>Laparoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

